Pharsight

Drugs that contain Letermovir

1. Prevymis patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8513255 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(2 months from now)

USRE46791 MERCK SHARP DOHME Substituted dihydroquinazolines
May, 2024

(2 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10603384 MERCK SHARP DOHME Pharmaceutical composition containing an antivirally active dihydroquinazoline derivative
Feb, 2033

(9 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Jun 5, 2030
New Dosing Schedule (D) Aug 2, 2026
New Indication (I) Jun 5, 2026

Market Authorisation Date: 08 November, 2017

Treatment: NA

Dosage: SOLUTION;INTRAVENOUS

More Information on Dosage

PREVYMIS family patents

Family Patents